Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Yige WuSiqi ChenXiaolu YangKazuhito SatoPreet LalYuefan WangAndrew T ShinkleMichael C WendlTina M PrimeauYanyan ZhaoAlanna GouldHua SunJacqueline L MuddJeremy HoogR Jay MashlMatthew A WyczalkowskiChia-Kuei MoRuiyang LiuJohn M HerndonSherri R DaviesDi LiuXi DingYvonne A EvrardBryan E WelmDavid H LumMei Yee KohAlana L WelmJeffrey H ChuangJeffrey A MoscowFunda Meric-BernstamRamaswamy GovindanShunqiang LiJames J HsiehRyan C FieldsKian-Huat LimCynthia X MaHui ZhangLi DingFeng ChenPublished in: Cancer research (2023)
The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.